Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The inaugural Intercepting Blood Cancers (IBC) 2023 Meeting brought together leading experts to discuss precursor conditions in blood cancers including monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma, myelodysplastic syndromes (MDS) and clonal hematopoiesis of indeterminate potential (CHIP), multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS).
MBL-CLL/Low-grade Lymphoma
Topic 1.2: The role of MBL in the etiology of CLL
MBL-CLL/Low-grade Lymphoma
Topic 1.3: Precursor conditions in Waldenström Macroglobulinemia
MBL-CLL/Low-grade Lymphoma
Topic 2.1: Overview of progression in MBL
MBL-CLL/Low-grade Lymphoma
Topic 2.2: Indolent to aggressive: Progression of CLL and FL
MBL-CLL/Low-grade Lymphoma
Topic 3.1: Overview of ongoing clinical studies and preliminary data
MBL-CLL/Low-grade Lymphoma
Topic 4.1: TCUS and T-cell LGL leukemia – laboratory diagnostics
CHIP/MDS
Topic 1.1 Genomics/observational
CHIP/MDS
Topic 1.2: Molecular mechanisms
CHIP/MDS
Topic 2.1: Prediction of adverse outcomes
CHIP/MDS
Topic 2.2: Clonal hematopoiesis in the clinics
CHIP/MDS
Topic 3.1: Pre-clinical
CHIP/MDS
Topic 3.2: Clinical
MM/SMM/MGUS
Topic 1.1: Genomics of MGUS and SMM
MM/SMM/MGUS
Topic 1.2: Animal models to study disease progression
MM/SMM/MGUS
Topic 1.3: Immune microenvironment of MGUS and smoldering myeloma
MM/SMM/MGUS
Topic 2.1: MGUS/SMM screening and risk
MM/SMM/MGUS
Topic 2.2: Risk factors and classification in SMM
MM/SMM/MGUS
Topic 3.1: Clinical trials
Keynote: FDA presentation (plenary session)